June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Longitudinal development of refractive error and visual acuity in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity
Author Affiliations & Notes
  • Michael Simmons
    Ophthalmology, UT Southwestern, Southlake, Texas, United States
  • Jingyun Wang
    College of Optometry, Salus University Pennsylvania, Pennsylvania, United States
  • Joel Leffler
    Ophthalmology, UT Southwestern, Southlake, Texas, United States
  • Shanshan Li
    MassMutual Data Science, Massachusetts, United States
  • Sarah Morales
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Angie Stephanie De La Cruz
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Eileen E Birch
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Footnotes
    Commercial Relationships   Michael Simmons, None; Jingyun Wang, None; Joel Leffler, None; Shanshan Li, None; Sarah Morales, None; Angie De La Cruz, None; Eileen Birch, None
  • Footnotes
    Support  EY022313, EY026664
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2134. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Simmons, Jingyun Wang, Joel Leffler, Shanshan Li, Sarah Morales, Angie Stephanie De La Cruz, Eileen E Birch; Longitudinal development of refractive error and visual acuity in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2134.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previous studies of retinopathy of prematurity treatment have showed a potential advantage of intravitreal bevacizumab (IVB) over laser photocoagulation due to a reduced prevalence of myopia and high myopia (> 5D myopia) in IVB-treated infants. However, the longitudinal patterns of refractive error development contributing to this difference have not been reported. This prospective cohort study compared longitudinal refractive error and visual acuity development during the first 3.5 years of life in children with severe ROP treated with IVB or laser.

Methods : Preterm infants (BW<1000g, GA 23-27 weeks) with Type 1 ROP were enrolled: IVB Group (N=22); Laser Group (N=26). Cycloplegic retinoscopy was conducted from 0.2 years corrected age and every 0.5-1.0 years thereafter until 3.5 years. Refractive error development was estimated with spherical equivalent, magnitude of astigmatism, and anisometropia. A linear mixed effect model was used to estimate the rate of individual development for each parameter. The model provided comparisons within each group as well as between groups.

Results : At the final visit, the prevalence of myopia was 82.7% in the laser group and 47.7% in the IVB group (P<0.05) with a final mean spherical equivalent refractive error of -8.0±5.8 D in the laser group vs -2.3±4.2 D in the IVB group (P<0.001). Longitudinal SEQ in both groups was best fit with a bilinear model (Figure 1). Before 1 year, the rate of SEQ change was -6.0D/YR in the laser group and -4.4D/YR in the IVB group (P<0.001). After 1 year, the slopes were not significantly different (laser: -0.3D/YR; IVB: 0.5D/YR; P=0.09). The magnitude of astigmatism increased significantly with age at a similar rate (0.19D/YR) in both groups. Anisometropia significantly increased with age in both groups but was lower in the IVB group (0.34D/YR) than in the laser group (0.55D/YR). Final visual acuity in both groups was 0.47 logMAR, equivalent to a Snellen acuity of 20/60.

Conclusions : IVB-treated infants developed significantly less myopia than laser-treated infants, largely due to a slower rate of refractive change during the first year of life. In both groups, the magnitude of anisometropia and astigmatism increased with age. Visual acuity also improved in both groups with age.

This is a 2020 ARVO Annual Meeting abstract.

 

Figure 1: Individual SEQ and the best-fit model over time

Figure 1: Individual SEQ and the best-fit model over time

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×